Last 46 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 0.15 | — | — | — | 0.07 | — | — | — | 0.00 | — | — | — | 0.00 |
| — | — | — | — | +84583.0% | — | — | — | -89.9% | — | — | — | — | |
| P/S Ratio | 4607.73 | 2.35 | 1.40 | 3.28 | 4.33 | 1.56 | — | — | — | — | — | — | — |
| — | +50.4% | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 0.07 | 0.46 | 0.28 | 0.27 | 0.29 | — | — | — | — | — | — | — | 5.20 |
| — | — | — | — | — | — | — | — | — | — | — | — | -78.6% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | 1.10 | — | — | — | 0.60 | — | 0.74 | 4.37 |
| — | — | — | — | — | +82.7% | — | — | — | — | — | -49.0% | — | |
| EV / EBIT | — | — | — | — | 0.06 | — | — | — | — | — | — | — | 5.25 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Scinai Immunotherapeutics Ltd.'s operating margin was -486.8% in Q2 2025, down 0.0 pp QoQ and down 1879.4 pp YoY. The trailing four-quarter average of -878.2% lags the current quarter, suggesting the recent improvement is above-trend. Gross margin contracted 184.5% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -88.1% | -164.3% | -164.3% | -81.1% | -148.2% | -57.7% | — | — | — | — | — | — | — |
| — | -184.5% | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | -1312.8% | -486.8% | -486.8% | -1098.5% | -1440.5% | 1392.6% | — | — | — | — | — | — | — |
| — | -135.0% | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | 728.9% | -534.8% | -400.8% | -1082.5% | 6223.2% | -817.6% | — | — | — | — | — | — | — |
| — | +34.6% | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 177.4% | -26.3% | -17.4% | -22.3% | 769.0% | — | — | — | — | — | — | -122.4% | 53.9% |
| — | — | — | — | — | — | — | — | — | — | — | -217.2% | +146.0% | |
| ROA | 31.0% | -17.5% | -12.3% | -17.3% | 77.1% | -14.6% | -12.5% | -12.9% | 16.1% | -17.4% | -14.0% | -2.2% | 4.6% |
| — | -19.9% | +2.1% | -34.2% | +377.6% | +16.4% | +10.4% | -486.7% | +248.9% | -58.6% | -74.6% | -152.9% | +143.0% | |
| ROIC | -61.1% | -15.3% | -14.6% | -16.7% | -17.6% | 28.0% | -14.1% | -12.5% | -15.2% | 76.1% | -35.7% | 37.1% | 6.8% |
| — | -154.5% | -3.5% | -33.8% | -15.6% | -63.2% | +60.5% | -133.7% | -322.2% | +475.9% | -125.3% | -18.7% | +145.9% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has weakened 67.5% YoY to 0.71x, tightening the short-term liquidity position.
| Metric | TTM | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.21 | 0.30 | 0.30 | 0.21 | 0.12 | — | — | — | — | — | — | — | 6.63 |
| — | — | — | — | — | — | — | — | — | — | — | — | -61.0% | |
| Debt / EBITDA | — | — | — | — | — | 4.68 | — | — | — | 2.70 | — | 4.83 | 13.36 |
| — | — | — | — | — | +73.2% | — | — | — | — | — | +31.0% | — | |
| Current Ratio | 1.32 | 0.71 | 0.71 | 1.32 | 1.16 | 2.19 | 2.73 | 3.06 | 4.36 | 4.12 | 4.28 | 6.15 | 5.75 |
| — | -67.5% | -74.0% | -56.7% | -73.4% | -46.9% | -36.3% | -50.2% | -24.1% | +141.2% | -26.4% | -15.8% | +1019.5% | |
| Quick Ratio | 1.32 | 0.71 | 0.71 | 1.32 | 1.16 | 2.19 | 2.73 | 3.06 | 4.36 | 4.12 | 4.28 | 6.15 | 5.75 |
| — | -67.5% | -74.0% | -56.7% | -73.4% | -46.9% | -36.3% | -50.2% | -24.1% | +141.2% | -26.4% | -15.8% | +1019.5% | |
| Interest Coverage | -6.00 | -10.14 | -171.95 | -61.16 | -1.28 | 13.46 | -8.79 | -3.56 | — | 7.77 | -9.78 | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 46 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonScinai Immunotherapeutics Ltd.'s current P/E is 0.1x. The average P/E over the last 1 quarters is 0.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Scinai Immunotherapeutics Ltd.'s current operating margin is -1312.8%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Scinai Immunotherapeutics Ltd.'s business trajectory between earnings reports.